Life Sciences Tools and Services
Company Overview of NuGEN Technologies, Inc.
NuGEN Technologies, Inc. provides genomics sample preparation solutions. It offers RNA and DNA sample preparation technologies for discovery and clinical research applications for life scientists; an approach to sample preparation based on the use of digital microfluidics for liquid handling; and automation solutions to streamline sample preparation technologies for sequencing, microarray analysis, and qPCR. The company offers its products for DNA analysis applications, such as next-gen sequencing, and microarrays and qPCR; and RNA analysis applications, including gene expression profiling. It offers its products through a network of distributors in the United States, Europe, Canada, Japan, ...
201 Industrial Road
San Carlos, CA 94070
Founded in 2000
Key Executives for NuGEN Technologies, Inc.
Chief Executive Officer and Director
Vice President of Operations
Vice President of Marketing
Compensation as of Fiscal Year 2014.
NuGEN Technologies, Inc. Key Developments
NuGEN Technologies, Inc. Launches Target Enrichment Technology
Jun 4 14
NuGEN Technologies, Inc. has launched a novel technology to better enable targeted sequencing studies with genomic DNA or RNA. This launch follows a early access period where the technology has been evaluated in leading genomics labs. NuGEN's proprietary method provides sensitive variant detection, including SNPs, indels, translocations, gene fusions and alternative splicing events with more uniform coverage and lower drop-out rates than currently available bait-capture methods. The method features a rapid and convenient workflow that can be used with genomic material from both fresh and formalin-fixed paraffin-embedded tissues, saving time and expanding sample sources available to the user. The Ovation Custom Target Enrichment System employs NuGEN's Single Primer Enrichment Technology (SPET), and is a complete library and enrichment solution for generation of enriched, multiplexed libraries from low-input amounts of genomic DNA or from cDNA. SPET technology is uniquely designed to provide independent coverage of target regions from both DNA strands, resulting in generation of high quality sequencing data. The rapid, low cost and extremely flexible custom design process has a three week delivery time, and is suitable for use in a range of applications including enrichment for exonic regions, splice variant and gene fusion analysis, long contiguous regions such as mitochondrial DNA and amplified genomic material from single cells. In addition to custom target enrichment offerings, NuGEN is introducing two standard oncological panels for DNA and RNA, respectively. The Ovation Cancer Panel Target Enrichment System enriches over 300 genes associated with cancer and the Ovation Gene Fusion Target Enrichment System is the first truly comprehensive fusion panel of over 400 cancer genes involved in gene fusions. Both systems are available as 8-reaction test kits or 32 and 96 reaction kits.
NuGEN's Novel Technology for RNA-Seq Extends to a Broad Range of Transcript Species
Apr 24 14
NuGEN Technologies, Inc. has developed a novel solution that enables more informative data to be generated from RNA-Seq studies performed with challenging samples, including model organisms. Human and non-human samples often have uninformative transcript species present in high abundance that can compromise data quality and cost-effectiveness of sequencing. NuGEN's proprietary technology provides targeted depletion of a broad range of uninformative transcripts, a solution not addressed by standard library preparation methods for RNA-Seq. NuGEN's novel method, Insert Dependent Adaptor Cleavage (InDA-C), employs primers during library creation to target specific transcripts for depletion in the final library and is the core technology employed in the Ovation Universal RNA-Seq Library System. Importantly, the method does not perturb the original total RNA input to the workflow. NuGEN provides a no-cost design service to assist researchers in choosing InDA-C primers, and primers can be designed for use with virtually any organism. The result is a significant reduction in sequencing reads derived from unwanted transcripts, including ribosomal RNA, globin and protein-coding RNAs, such as housekeeping genes. Unlike methods that use hybridization-mediated pull-down strategies to deplete unwanted RNA species, the InDA-C method avoids off-target mRNA cross-hybridization events that can potentially introduce bias.
NuGEN Technologies, Inc Expands Portfolio of Clinical Sample Solutions
Sep 24 13
NuGEN Technologies, Inc. announced the release of the Ovation Human FFPE RNA-Seq Multiplex System. This kit, optimized for use with human samples, provides an end-to-end solution for strand-specific RNA-Seq library construction using very low input amounts of total RNA derived from formalin-fixed paraffin embedded tissues, and is also suitable for RNA obtained from fresh frozen human tissues or cell lines. The Ovation Human FFPE RNA-Seq Multiplex System complements the recently launched Ovation Human Blood RNA-Seq Multiplex System and together they provide highly effective RNA-Seq sample preparation for the most common sample types handled in clinical research laboratories. One of the difficulties inherent in FFPE and blood samples respectively is the high abundance of human ribosomal RNA and adult human reticulocyte globin. To address this challenge, NuGEN has developed the novel and proprietary Insert Dependent Adaptor Cleavage (InDA-C) technology. InDA-C provides targeted depletion of unwanted high abundance transcripts for more efficient use of sequencing resources and eliminates the need for additional hybridization based capture steps. This technology is employed in both the Ovation Human FFPE RNA-Seq Multiplex System and the Ovation Human Blood RNA-Seq Multiplex Systems or can be configured as a custom solution to eliminate any transcripts defined by the user prior to sequencing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|